FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Sandostatin LAR Depot (octreotide acetate) by Novartis, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly
• Carcinoid Syndrome
• Neuroendocrine Tumor

Drugs mentioned

• SANDOSTATIN LAR DEPOT (OCTREOTIDE ACETATE)

Snippet

SUPPL AP for SANDOSTATIN LAR DEPOT (OCTREOTIDE ACETATE)